Senti Biosciences, Inc. (SNTI) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Senti Biosciences reported revenue of $22,000. Net income was -$61.4M (a -279263.6% net margin), or -$2.73 per diluted share. Operating margin was -312631.8%. Operating activities generated -$43.4M of cash, leaving -$43.6M of free cash flow. At fiscal year end, Senti Biosciences held $51.2M in total assets against $45.6M in total liabilities, including $16.4M of cash and equivalents.
Open the full interactive Senti Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Senti Biosciences Key Stats
| Share Price | $0.25 |
|---|---|
| Market Cap | $7.9M |
| 52-Week Range | $0.25 – $2.39 |
| Shares Outstanding | 31.1 million (basic, 2026 Q2) |
Senti Biosciences Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $4.3M | $2.6M | $0 | $22,000 |
| Operating Income | -$70.6M | -$92.7M | -$61.0M | -$68.8M |
| Pre-Tax Income | -$58.2M | -$71.1M | -$52.8M | -$61.4M |
| Income Tax | — | — | — | $0 |
| Net Income | -$58.2M | -$71.1M | -$52.8M | -$61.4M |
| Diluted EPS | -$22.30 | -$16.00 | -$12.03 | -$2.73 |
Senti Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | — | $16,000 | $17,000 |
| Net Income | -$18.1M | -$14.5M | -$4.2M | -$12.8M |
| Diluted EPS | -$0.69 | -$0.64 | -$0.14 | -$0.41 |
Senti Biosciences Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $57.6M | $35.9M | $48.3M | $16.4M |
| Current Assets | $102.6M | $71.2M | $59.0M | $23.3M |
| Total Assets | $180.8M | $119.5M | $97.8M | $51.2M |
| Current Liabilities | $18.1M | $12.7M | $13.1M | $14.0M |
| Total Liabilities | $53.5M | $52.6M | $47.1M | $45.6M |
| Shareholders' Equity | $127.3M | $66.9M | $25.6M | $5.6M |
Senti Biosciences Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$34.9M | -$52.4M | -$41.4M | -$43.4M |
| Cash From Investing | -$82.0M | $30.1M | $34,000 | -$184,000 |
| Cash From Financing | $118.6M | $779,000 | $53.7M | $11.8M |
| Free Cash Flow | -$76.3M | -$64.4M | -$41.4M | -$43.6M |
Figures from Senti Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Senti Biosciences financials page for every line item.
Senti Biosciences Company Profile
| Ticker | SNTI |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001854270 |
Frequently Asked Questions
What was Senti Biosciences' revenue in fiscal 2025?
Senti Biosciences (SNTI) reported revenue of $22,000 for fiscal 2025.
What is Senti Biosciences' annual revenue history?
Senti Biosciences' annual revenue by fiscal year: 2022: $4.3M; 2023: $2.6M; 2024: $0; 2025: $22,000.
What was Senti Biosciences' net income in fiscal 2025?
Senti Biosciences reported net income of -$61.4M for fiscal 2025.
What was Senti Biosciences' earnings per share (EPS) in fiscal 2025?
Senti Biosciences' diluted EPS was -$2.73 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Senti Biosciences generate in fiscal 2025?
Senti Biosciences generated -$43.6M of free cash flow in fiscal 2025.
What was Senti Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Senti Biosciences reported revenue of $17,000.
How many shares of Senti Biosciences are outstanding?
Senti Biosciences reported a weighted average of 31.1 million basic shares outstanding in 2026 Q2.
What is Senti Biosciences' market cap?
Based on its latest closing price, Senti Biosciences (SNTI) has a market capitalization of about $7.9M.
When does Senti Biosciences' fiscal year end?
Senti Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Senti Biosciences headquartered?
Senti Biosciences lists its business address in South San Francisco, California in its SEC filings.
Senti Biosciences Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →